Kiniksa Pharmaceuticals Ltd

Stock Chart, Company Information, and Scan Results

$32.95(as of Aug 4, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Kiniksa Pharmaceuticals Ltd Company Information, Fundamentals, and Technical Indicators

Stock Price$32.95
Ticker SymbolKNSA
ExchangeNasdaq
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees315
CountyUSA
Market Cap$2,370.0M
EBIDTA6.0M
10-Day Moving Average29.07
P/E Ratio536.16
20-Day Moving Average28.76
Forward P/E Ratio0.00
50-Day Moving Average28.44
Earnings per Share0.05
200-Day Moving Average23.55
Profit Margin11.37%
RSI70.72
Shares Outstanding43.5M
ATR1.29
52-Week High33.10
Volume848,345
52-Week Low17.82
Most Recent Support Level26.27
Book Value495.0M
Most Recent Resistance Level31.92
P/B Ratio5.19
Upper Keltner31.66
P/S Ratio4.85
Lower Keltner25.87
Debt-to-Equity Ratio31.66
Next Earnings Date11/04/2025
Cash Surplus74.2M
Next Ex-Dividend DateUnknown

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.

Kiniksa Pharmaceuticals Ltd In Our Stock Scanner

As of Aug 05, 2025
example chart graphic
Scan Name: 52-Week HighScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Doji CandlesScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Dragonfly DojiScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Increasing Book ValueScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.